TNFRSF10A and cancer: High TRAIL-R1 or TRAIL-R2 expression was associated with a less aggressive phenotype characterized by early AJCC stage, well-differentiated tumors, microsatellite stable cancers, absence of KRAS mutations and expression of pro apoptotic molecules: KRAS4A, p27kip1 and cleaved caspase 3.